|Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors|
DA Wainwright, AL Chang, M Dey, IV Balyasnikova, CK Kim, A Tobias, ...
Clinical cancer research 20 (20), 5290-5301, 2014
|IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival|
DA Wainwright, IV Balyasnikova, AL Chang, AU Ahmed, KS Moon, ...
Clinical cancer research 18 (22), 6110-6121, 2012
|CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells|
AL Chang, J Miska, DA Wainwright, M Dey, CV Rivetta, D Yu, D Kanojia, ...
Cancer research 76 (19), 5671-5682, 2016
|Blood‐brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging|
Y Cheng, Q Dai, RA Morshed, X Fan, ML Wegscheid, DA Wainwright, ...
Small 10 (24), 5137-5150, 2014
|Reduced skin homing by functional Treg in vitiligo|
J Klarquist, CJ Denman, C Hernandez, DJ Wainwright, FM Strickland, ...
Pigment cell & melanoma research 23 (2), 276-286, 2010
|Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy|
L Zhai, S Spranger, DC Binder, G Gritsina, KL Lauing, FJ Giles, ...
Clinical cancer research 21 (24), 5427-5433, 2015
|Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma|
EJ Chung, Y Cheng, R Morshed, K Nord, Y Han, ML Wegscheid, ...
Biomaterials 35 (4), 1249-1256, 2014
|Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors|
DA Wainwright, S Sengupta, Y Han, MS Lesniak
Neuro-oncology 13 (12), 1308-1323, 2011
|The challenge for gene therapy: innate immune response to adenoviruses|
B Thaci, IV Ulasov, DA Wainwright, MS Lesniak
Oncotarget 2 (3), 113, 2011
|IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection|
J Xin, DA Wainwright, NA Mesnard, CJ Serpe, VM Sanders, KJ Jones
Brain, behavior, and immunity 25 (5), 820-829, 2011
|Targeting Tregs in malignant brain cancer: overcoming IDO|
Frontiers in immunology 4, 116, 2013
|Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model|
AU Ahmed, CE Rolle, MA Tyler, Y Han, S Sengupta, DA Wainwright, ...
Molecular Therapy 18 (10), 1846-1856, 2010
|Immunotherapy for cancer in the central nervous system: current and future directions|
DC Binder, AA Davis, DA Wainwright
Oncoimmunology 5 (2), e1082027, 2016
|Nanoparticle‐Programmed Self‐Destructive Neural Stem Cells for Glioblastoma Targeting and Therapy|
Y Cheng, R Morshed, SH Cheng, A Tobias, B Auffinger, DA Wainwright, ...
Small 9 (24), 4123-4129, 2013
|Recent developments on immunotherapy for brain cancer|
DA Wainwright, P Nigam, B Thaci, M Dey, MS Lesniak
Expert opinion on emerging drugs 17 (2), 181-202, 2012
|The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma|
DA Wainwright, S Sengupta, Y Han, IV Ulasov, MS Lesniak
PloS one 5 (10), e15390, 2010
|Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model|
S Sengupta, S Nandi, ES Hindi, DA Wainwright, Y Han, MS Lesniak
Neoplasia (New York, NY) 12 (10), 837, 2010
|The role of IDO in brain tumor immunotherapy|
L Zhai, KL Lauing, AL Chang, M Dey, J Qian, Y Cheng, MS Lesniak, ...
Journal of neuro-oncology 123 (3), 395-403, 2015
|Phenotype of CD4+ T cell subsets that develop following mouse facial nerve axotomy|
J Xin, DA Wainwright, CJ Serpe, VM Sanders, KJ Jones
Brain, behavior, and immunity 22 (4), 528-537, 2008
|IDO1 in cancer: a Gemini of immune checkpoints|
L Zhai, E Ladomersky, A Lenzen, B Nguyen, R Patel, KL Lauing, M Wu, ...
Cellular & molecular immunology 15 (5), 447-457, 2018